AOD-9604 in Burnham — Fat Loss Peptide Research Guide
AOD-9604 research guide for Burnham. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Most researchers trying to source AOD-9604 in Burnham quickly find that local retail options are virtually absent. What this means for Burnham researchers is that geography is secondary to your ability to evaluate vendor quality — and those evaluation tools are available to every researcher. The core quality markers for AOD-9604 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. Use this guide to evaluate AOD-9604 vendors rigorously — the standards covered in this guide work regardless of your location.
AOD-9604: What the Research Shows
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Burnham studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
AOD-9604 Purchasing Guide
Assessing AOD-9604 vendors starts with the COA: access the batch-specific certificate before placing an order, not after. The HPLC chromatogram is the most important document in the COA: it should show a large primary peak representing AOD-9604, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. For Burnham researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before scaling up your order is what experienced peptide researchers consistently do. Price is an ineffective primary criterion for AOD-9604 quality — research-grade synthesis and testing has unavoidable expenses that low-priced vendors are not absorbing, so unusually low prices consistently indicate quality reductions.
Order AOD-9604 — ships to Burnham
COA-verified · International tracking · Research grade
AOD-9604 is available for research use only and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is educational. Temperature excursions — even temporary temperature deviation — can partially degrade AOD-9604 without detectable changes to appearance; always maintain cold chain and work with cold-shipped material. The main safety concern arising from sourcing in AOD-9604 research is endotoxin from inadequately tested product — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. For any individual considering AOD-9604 outside a formal research context: seek medical advice first — this compound is not approved for human use and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
